10x Genomics, Inc. (TXG) Stock Price & How to Invest

Last updated November 2026

Short answer

TXG is 10x Genomics, a leading maker of single-cell and spatial biology tools (Chromium, Visium, Xenium, and the new Atera platform) sold mostly to academic and biopharma researchers. It is a growth-story life-science name whose revenue is roughly flat right now because tight research budgets are squeezing instrument sales, yet the stock has re-rated sharply in 2026: as of October 16 it closed at about $69.53, up roughly 318% year to date and 462% over one year. The picture hinges on whether recurring consumables and the Atera launch can reaccelerate growth enough to justify that move.

TXG stock price

As of 2026-11-16, 10x Genomics, Inc. (TXG) last closed at $54.99, up 250.3% over the past year. Over the past 52 weeks it has traded between $15.46 and $97.74.

TXG last close
$54.99
1 day
-5.50%
1 month
-21.29%
1 year
+250.25%
52-week range
$15.46 to $97.74
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or 10x Genomics, Inc.'s investor relations page. Walnut is informational, not investment advice.

TXG key stats

At $54.99 on November 16, 2026, 10x Genomics, Inc. (TXG) has a market cap of $7.2B.

Market cap
$7.2B
P/E (forward)
634.5
Price to book
8.6
Beta
2.03

Market cap, P/E and yield are measured at the $54.99 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with 10x Genomics, Inc. (TXG)?

The last two weeks for 10x Genomics, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • TXG closed at $54.99 on November 16, 2026, down 15.5% over the past five trading days (from $65.05).
  • On November 6, 2026, 10x Genomics, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 5, 2026, 10x Genomics, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
  • On November 9, 2026, JP Morgan lowered its target to $65.00 from $70.00 (Neutral).
  • On November 9, 2026, Barclays lowered its target to $70.00 from $110.00 (Overweight).
  • On November 6, 2026, UBS lowered its target to $61.00 from $90.00 (Neutral).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

10x Genomics, Inc. (TXG) latest quarter

10x Genomics reported revenue of $151 million for Q3 2026, up 1% from a year earlier (10x Genomics, Nov 5, 2026).

Revenue
$151 million
up 1% from a year earlier
Diluted EPS
-$0.15
n/a
Instruments
$6.9 million
down 43% from a year earlier

Source: 10x Genomics Q3 2026 results release, Nov 5, 2026. Full earnings breakdown

What does 10x Genomics, Inc. (TXG) do?

10x Genomics, Inc. (Nasdaq: TXG) builds instruments, reagents, and software for single-cell and spatial biology, the tools scientists use to read gene activity one cell at a time and map it across intact tissue. Its core franchises are Chromium (single-cell analysis), the Visium and Xenium spatial platforms, and the newly launched Atera in situ system (list price around $495,000, shipping in the second half of 2026). Revenue skews toward recurring consumables sold to academic labs, pharma and biotech research groups, and core genomics facilities, with instrument placements driving the razor-and-blade model over time.

The investment picture is a category leader growing slowly through a rough patch while the share price races ahead. Trailing-twelve-month revenue is roughly $617M with the company still running a net loss of about $75M, though gross margin holds near 70%, free cash flow over the last twelve months was about $180M, and the balance sheet carries roughly $552M of cash against about $79M of debt. Full-year 2026 guidance of $600M to $625M implies only 0% to 4% growth after stripping out one-time patent-settlement revenue, a result of a deep freeze in academic and biopharma capital-equipment budgets (instrument sales fell about 24% year over year in Q1). The stock (market cap roughly $9.1B, price-to-sales near 15x as of October 16, 2026) is priced on the expectation that consumables growth and new platforms like Atera eventually reaccelerate the top line. Second-quarter 2026 revenue was about $151M, roughly level with the first quarter and about 13% lower year over year against a prior-year period that included patent-settlement revenue.

What's driving 10x Genomics, Inc. (TXG)?

1. Consumables-led recurring revenue

Even with instrument sales frozen, consumables grew about 13% year over year in Q1 2026 as the large installed base of Chromium and spatial instruments keeps ordering reagents. This recurring, higher-margin revenue is the ballast that helped lift gross margin toward 70% and narrow losses. A growing installed base compounds this stream over time.

2. New platform launches (Atera and spatial)

10x launched the Atera in situ platform in April 2026, promising whole-transcriptome spatial analysis at single-cell resolution, with shipments starting in the second half of the year. Xenium and Visium continue to expand the spatial franchise. New instruments both seed future consumables pull-through and defend the company's technology leadership. In October 2026 BofA Securities raised its price target to $80 from $50 (keeping a Neutral rating), citing improving sentiment, growing consumables revenue and initial traction for Atera.

3. Market leadership and consolidation

10x is the recognized leader across single-cell and spatial biology, and the space has consolidated (former rival NanoString went through bankruptcy and is now Bruker Spatial). That created an opening to capture displaced customers. The company is also pushing single-cell technology toward clinical and diagnostic applications, a potential longer-term expansion beyond research. On October 7, 2026 the company announced a research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial applications across solid tumors and blood cancers, a step toward that clinical biomarker work.

4. Margin and cost discipline

Operating expenses fell about 15% year over year in Q1 2026 on lower legal, personnel, and marketing costs, and gross margin rose on fewer inventory write-downs and warranty charges. Net losses have narrowed from about $255M in 2023 to about $44M in 2025, and adjusted EPS has beaten consensus in each of the last four quarters (for example $0.03 against an expected -$0.02 in Q2 2026). With roughly $552M of cash and about $180M of trailing free cash flow, the company has runway to fund launches while it works toward sustained profitability.

What are the risks to 10x Genomics, Inc. (TXG)?

The biggest overhang is demand: U.S. academic and NIH-linked research funding plus biopharma capital budgets have tightened sharply, and instrument sales dropped about 24% year over year, driving management's flat guidance. The company is still unprofitable on a net basis (about -$75M over the trailing twelve months), so the valuation, now near 15x sales after a 318% gain in 2026, leans heavily on a growth reacceleration that may not arrive on schedule. Consensus still expects 2026 revenue of only about $621M and 2027 revenue of about $684M. The stock is extremely volatile: its 52-week range runs from about $11.81 to $102.81, and it fell about 9% over the month to October 16. Competition is intensifying from Illumina, Bruker Spatial, Bio-Techne, Akoya, Vizgen, Bio-Rad, and newer single-cell entrants, and 10x has a long history of patent litigation whose settlements produced non-recurring revenue that will not repeat. New-platform adoption (Atera) is unproven at scale, and results can be lumpy quarter to quarter.

What is the 10x Genomics, Inc. (TXG) forecast?

14 analysts publish price targets on TXG, averaging $68.14 as of November 2026, or +23.9% against the $54.99 share price on November 16, 2026. The published targets run from $50.00 to $100.00, a wide spread, and the ratings split 6 buy, 11 hold, 0 sell. Over the last six months there have been 8 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full TXG forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is TXG a buy or a sell?

We give no verdict on 10x Genomics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Consumables-led recurring revenue. Even with instrument sales frozen, consumables grew about 13% year over year in Q1 2026 as the large installed base of Chromium and spatial instruments keeps ordering reagents. The most optimistic published target, $100.00, assumes this works close to its best case.

The case against. The biggest overhang is demand: U.S. The most pessimistic target, $50.00, is roughly what TXG is worth if this bites instead.

Read the full bull and bear case on TXG, including what would have to change to break either one. Walnut is not an investment adviser.

Has 10x Genomics, Inc. (TXG) split its stock?

No. 10x Genomics, Inc. (TXG) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is 10x Genomics, Inc. (TXG) valued?

Market cap, P/E and dividend yield at today's price are in the TXG key stats above. The business figures below come from 10x Genomics, Inc.'s reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$617M
  • Q2 2026 revenue: ~$151M (~-13% YoY vs a settlement-boosted prior year)
  • Gross / operating margin: ~70% / ~-15%
  • Net income (TTM): ~-$75M
  • Free cash flow (TTM): ~$180M
  • Cash / debt: ~$552M / ~$79M

As of October 2026: 10x Genomics trades at roughly 15x sales while revenue is essentially flat and the company still runs a net loss, so the market is paying for future growth rather than current profits; the multiple has roughly doubled since mid-2026. Consensus for the September quarter, due November 5, 2026, is about $148M of revenue and an adjusted loss of $0.02 per share. The key swing factor remains whether academic and biopharma spending thaws, and Atera orders build, enough to restart instrument placements.

Which ETFs hold 10x Genomics, Inc. (TXG)?

If you want TXG exposure as part of a larger bundle, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

ETFName% in TXGExpense ratio
ARKGARK Genomic Revolution ETF10.0%0.75%
ARKKARK Innovation ETF3.49%0.75%
IWMiShares Russell 2000 ETF0.36%0.19%
SCHASchwab U.S. Small-Cap ETF0.26%0.03%
IWOiShares Russell 2000 Growth ETF0.70%0.24%

Who competes with 10x Genomics, Inc. (TXG)?

Spatial biology specialists

Bruker Spatial Biology (the former NanoString GeoMx and CosMx lines), Akoya Biosciences, and Vizgen compete directly with 10x's Visium and Xenium spatial platforms for tissue-mapping customers.

Broad genomics and sequencing tools

Illumina (which acquired single-cell player Fluent BioSciences), Bio-Rad Laboratories, and Bio-Techne overlap in sample prep and genomics workflows and can bundle adjacent instruments to research customers.

Emerging single-cell entrants

Newer single-cell providers such as Parse Biosciences and Standard BioTools, plus academic and open-source methods, offer lower-cost or scalable alternatives that pressure pricing on 10x's Chromium franchise.

What stocks are similar to 10x Genomics, Inc. (TXG)?

Other names that sit close to TXG: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in 10x Genomics, Inc. (TXG)

There are three common ways to get TXG exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (ARKG, ARKK, IWM), which spreads the position across many companies. Or build it into a focused thematic portfolio, so TXG sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where TXG fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on 10x Genomics, Inc. (TXG)

10x Genomics is a category leader in single-cell and spatial genomics trading on future growth while near-term revenue stays flat under tight research funding. After a roughly fourfold rise in 2026 it is valued at about 15x trailing sales (market cap ~$9.1B in October 2026), so the stock now prices in an Atera-led reacceleration that the reported numbers have yet to show; third-quarter results on November 5, 2026 are the next check.

More on 10x Genomics, Inc. (TXG)

Whether TXG is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is TXG a buy or a sell?, and where the stock could go from here in the TXG stock forecast.

For income investors, whether TXG pays a dividend and how the payout looks is covered in does TXG pay a dividend? And to weigh TXG against a peer, read the full side-by-side comparisons: TXG vs BRKR and TXG vs ILMN.

Wondering how TXG fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about 10x Genomics, Inc.

Ask Walnut's AI anything about TXG and see how it fits what you own.

FAQ

What does TXG stand for and what does the company do?

+

TXG is the Nasdaq ticker for 10x Genomics, Inc. The company makes instruments, reagents, and software for single-cell and spatial biology, tools researchers use to measure gene activity in individual cells and map it across tissue. Its main products are Chromium, Visium, Xenium, and the new Atera platform.

Is 10x Genomics profitable?

+

Not yet on a net basis. The company reported net losses of about $13.5M in Q1 2026 and about $17.9M in Q2 2026, and about $75M over the trailing twelve months, though annual losses have narrowed sharply from about $255M in 2023. On an adjusted basis EPS has been slightly positive in recent quarters, and gross margin holds near 70%.

How fast is 10x Genomics growing?

+

Slowly right now. Full-year 2026 guidance of about $600M to $625M implies only 0% to 4% growth after excluding one-time patent-settlement revenue. Consumables grew about 13% in Q1, but instrument sales fell around 24% as research budgets tightened, holding overall growth back. Q2 2026 revenue was about $151M, and analysts expect about $621M for full-year 2026 and about $684M for 2027.

Why has TXG revenue been flat?

+

A freeze in U.S. academic and NIH-linked research funding and cautious biopharma capital-equipment budgets have sharply reduced new instrument purchases. Because instruments seed future consumables demand, the funding slowdown weighs on both current and future revenue until spending recovers.

What is the Atera platform?

+

Atera is 10x Genomics' in situ spatial biology system launched in April 2026, designed to deliver whole-transcriptome analysis at single-cell resolution and high throughput. It carries a list price around $495,000 and began shipping in the second half of 2026, and it is central to the company's next growth phase.

Who are 10x Genomics' main competitors?

+

In spatial biology it competes with Bruker Spatial (formerly NanoString), Akoya Biosciences, and Vizgen. In broader genomics tools it faces Illumina, Bio-Rad, and Bio-Techne, plus newer single-cell entrants such as Parse Biosciences and Standard BioTools.

How is TXG valued?

+

As of October 16, 2026 the market cap is roughly $9.1B against trailing revenue near $617M, a price-to-sales ratio around 15x, about double the level of mid-2026. That premium reflects 10x's category leadership and expected Atera-led growth rather than current earnings, since the company is not yet consistently profitable. Fifteen analysts carry a mean price target of about $77.

What are the biggest risks for TXG investors?

+

The main risks are continued weakness in academic and biopharma research funding, ongoing net losses, intensifying competition, reliance on unproven new-platform adoption, and lumpy quarterly results. Prior patent-settlement revenue was one-time and will not repeat, which flatters year-over-year comparisons.

How did 10x Genomics do in its latest quarter?

+

In the quarter ended June 30, 2026, 10x reported revenue of about $151M, roughly flat with Q1 and about 13% lower than a year earlier, when patent-settlement revenue inflated the comparison. The net loss was about $17.9M, while adjusted EPS of $0.03 beat the consensus estimate of -$0.02. Third-quarter results are scheduled for November 5, 2026, with consensus near $148M of revenue.

How has TXG stock performed in 2026?

+

Exceptionally, with large swings. As of the October 16, 2026 close of about $69.53, TXG was up roughly 318% year to date and 462% over one year, though down about 9% over the prior month. Its 52-week range is about $11.81 to $102.81. Walnut describes the stock and is not an investment adviser.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with 10x Genomics, Inc.'s investor relations page or your broker before making investment decisions.